Skip to main content
. Author manuscript; available in PMC: 2021 Jul 10.
Published in final edited form as: Sci Transl Med. 2021 Mar 10;13(584):eabb3945. doi: 10.1126/scitranslmed.abb3945

Fig. 1. ICP-MS analysis demonstrates Au accumulation in recurrent GBM patient tumors.

Fig. 1.

(A) Schematic of NU-0129. (B) Bcl2L12 mRNA with binding site for the siRNA oligonucleotide used to functionalize gold nanoparticle cores (nucleotide position 743–761; black box). Positions for nucleotides encoding the C-terminal BH2 are indicated (nucleotide position 931–972; red box). (C) ICP-MS analysis of bulk patient GBM tissue, including tumor recurrences post NU-0129 trial enrollment for patients 101 and 102; tumors recurred 159 and 174 days post NU-109 trial enrollment, respectively. n, number of tumor regions sampled. Dt, time from surgery to infusion. Shown is the median. Of note, tumor resections for patients 103 and 107 did not yield sufficient viable tumor tissue for ICP-MS.